Form 4: CEO Mark Goldsmith Executes Stock Options at Revolution

Revolution Medicines CEO Mark Goldsmith exercised 120,000 stock options and sold the resulting shares under a 10b5-1 plan.

Summary

• CEO Mark A. Goldsmith exercised options for 120,000 shares of common stock on April 15, 2026.
• The exercise involved 23,244 shares at $4.09 and 96,756 shares at $4.73.
• Following the exercise, 120,000 shares were sold at a weighted average price of $150.0874.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine, pre-planned divestment by an executive that does not signal a change in company fundamentals.

Positives

• The transaction was pre-planned under a 10b5-1 trading plan, indicating a systematic approach to liquidity rather than reactive selling.
• The CEO maintains a significant remaining beneficial ownership stake in the company.

Negatives

• The sale represents a divestment of 120,000 shares by the company's top executive.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The reporting person undertakes to provide full information regarding the number of shares and prices at which the transaction was effected upon request.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal financial planning while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for biotech executives to avoid allegations of insider trading.
• The scale of the sale is consistent with typical executive compensation and liquidity events for mid-to-large cap biotech firms.

Stakeholder Impact

• Shareholders should view this as a routine liquidity event for the CEO.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Options, 10b5-1